Accepted Articles
Back to the articles list |
Back to browse issues page
Fatemeh Zarei Hajiabadi1 
, Vajiheh Aghamollaii * 2, Padideh Ghaeli3 , Abolfazl Mohammadi4 , Samira Chaibakhsh5 , Sana Khajepour6
, Vajiheh Aghamollaii * 2, Padideh Ghaeli3 , Abolfazl Mohammadi4 , Samira Chaibakhsh5 , Sana Khajepour6
1- Clinical Pharmacist, School of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
2- Neuropsychiatry Department, Roozbeh Hospital, Tehran University of Medical sSciences (TUMS), Tehran, Iran.
3- Roozbeh Hospital and School of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
4- Department of Psychiatry, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
5- Research Center for Rational Use of Drugs, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
6- Faculty of Pharmacy, Department of Biomedical and Pharmaceutical Sciences, Idaho State University, Idaho, USA.
2- Neuropsychiatry Department, Roozbeh Hospital, Tehran University of Medical sSciences (TUMS), Tehran, Iran.
3- Roozbeh Hospital and School of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
4- Department of Psychiatry, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
5- Research Center for Rational Use of Drugs, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
6- Faculty of Pharmacy, Department of Biomedical and Pharmaceutical Sciences, Idaho State University, Idaho, USA.
Abstract:
Objective: Behavioral disorder is known as one of the most common side effects of levetiracetam (LEV). Previous studies in children and adolescents have noted the potential positive effects of pyridoxine in preventing these disorders. Pyridoxine (Vitamin B6) is a water-soluble vitamin playing a pivotal role as a co-factor in regulating more than 100 enzymatic reactions such as GABA and serotonin synthesis and catabolism. This study aims at investigating the effects of pyridoxine on behavioral disorders, including depression, anxiety, and stress caused by levetiracetam.
Method: A total of 38 patients who were prescribed levetiracetam by a neurologist were enrolled in the study following taking informed consent. They were randomly divided into two groups. A group of 19 people received pyridoxine 40 mg twice daily in the first two weeks and 40 mg 3 times per day for the next two weeks known as the intervention group. The remaining patients were taking only levetiracetam known as the control group. DASS 21 questionnaire was used to measure levetiracetam induced depression, anxiety, and stress at weeks 0 and 4.
Results: In this study, 19 patients received LEV in different doses, and 19 received LEV plus pyridoxine 40 mg twice daily for 2 weeks following a 40 mg three times daily for two more weeks. After 4 weeks of treatment with both LEV and LEV plus pyridoxine, the results revealed that two treatments equally induced the LEV induced symptoms. After 4 weeks of treatment, the results of this study did not show any significant differences between the intervention and control group.
Conclusion: This study suggests that pyridoxine may not be effective in preventing depression, anxiety, and stress-induced by levetiracetam in adult patients who are suffering from seizure disorders and are on levetiracetam.
Method: A total of 38 patients who were prescribed levetiracetam by a neurologist were enrolled in the study following taking informed consent. They were randomly divided into two groups. A group of 19 people received pyridoxine 40 mg twice daily in the first two weeks and 40 mg 3 times per day for the next two weeks known as the intervention group. The remaining patients were taking only levetiracetam known as the control group. DASS 21 questionnaire was used to measure levetiracetam induced depression, anxiety, and stress at weeks 0 and 4.
Results: In this study, 19 patients received LEV in different doses, and 19 received LEV plus pyridoxine 40 mg twice daily for 2 weeks following a 40 mg three times daily for two more weeks. After 4 weeks of treatment with both LEV and LEV plus pyridoxine, the results revealed that two treatments equally induced the LEV induced symptoms. After 4 weeks of treatment, the results of this study did not show any significant differences between the intervention and control group.
Conclusion: This study suggests that pyridoxine may not be effective in preventing depression, anxiety, and stress-induced by levetiracetam in adult patients who are suffering from seizure disorders and are on levetiracetam.
Type of Study: Original |
Subject:
Clinical Neuroscience
Received: 2020/06/4 | Accepted: 2021/04/17 | Published: 2023/09/29
Received: 2020/06/4 | Accepted: 2021/04/17 | Published: 2023/09/29
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
